$203.66
0.25% day before yesterday
NYSE, Dec 26, 10:00 pm CET

Charles River Laboratories International, Inc. Stock price

$203.66
+24.72 13.81% 1M
+52.07 34.35% 6M
+19.06 10.33% YTD
+17.01 9.11% 1Y
-14.84 6.79% 3Y
-43.51 17.60% 5Y
+123.96 155.53% 10Y
+160.95 376.84% 20Y
NYSE, Closing price Fri, Dec 26 2025
+0.50 0.25%

Key metrics

Basic
Market capitalization
$10.0b
Enterprise Value
$12.0b
Net debt
$2.0b
Cash
$207.2m
Shares outstanding
49.2m
Valuation (TTM | estimate)
P/E
negative | 19.7
P/S
2.5 | 2.5
EV/Sales
3.0 | 3.0
EV/FCF
22.0
P/B
2.9
Financial Health
Equity Ratio
46.0%
Return on Equity
0.3%
ROCE
7.4%
ROIC
25.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.0b | $4.0b
EBITDA
$671.4m | $983.4m
EBIT
$472.1m | $785.8m
Net Income
$-83.5m | $508.8m
Free Cash Flow
$543.7m
Growth (TTM | estimate)
Revenue
-0.9% | -0.1%
EBITDA
-9.5% | 42.7%
EBIT
-22.7% | 42.7%
Net Income
-120.2% | 4,839.7%
Free Cash Flow
-3.0%
Margin (TTM | estimate)
Gross
34.7%
EBITDA
16.7% | 24.3%
EBIT
11.7%
Net
-2.1% | 12.6%
Free Cash Flow
13.5%
More
EPS
$-1.7
FCF per Share
$11.0
Short interest
5.6%
Employees
19k
Rev per Employee
$210.0k
Show more

Is Charles River Laboratories International, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Charles River Laboratories International, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Charles River Laboratories International, Inc. forecast:

13x Buy
59%
9x Hold
41%

Analyst Opinions

22 Analysts have issued a Charles River Laboratories International, Inc. forecast:

Buy
59%
Hold
41%

Financial data from Charles River Laboratories International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,024 4,024
1% 1%
100%
- Direct Costs 2,628 2,628
1% 1%
65%
1,395 1,395
4% 4%
35%
- Selling and Administrative Expenses 724 724
1% 1%
18%
- Research and Development Expense - -
-
-
671 671
10% 10%
17%
- Depreciation and Amortization 199 199
52% 52%
5%
EBIT (Operating Income) EBIT 472 472
23% 23%
12%
Net Profit -83 -83
120% 120%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Charles River Laboratories International, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Charles River Laboratories International, Inc. Stock News

Neutral
Business Wire
15 days ago
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as we...
Neutral
Business Wire
22 days ago
BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles River Investment Management Solution (Charles River IMS). A Charles River client since 2002, T Rowe Price continues to deepen its engagement with Charles River Development to modernize front-office ope...
Neutral
Seeking Alpha
23 days ago
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
More Charles River Laboratories International, Inc. News

Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Head office United States
CEO James Foster
Employees 19,400
Founded 1947
Website www.criver.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today